Medical Applications of Gadolinium and/or Boron-Labeled Pharmaceuticals

PDF Version Also Available for Download.

Description

Boron neutron capture therapy (BNCT) is a binary treatment modality that can selectively irradiate tumor tissue. The key to effective BNCT is the preferential accumulation of <sup>10</sup>B in the tumor relative to the surrounding normal tissues. A screening procedure was developed under this CRADA that is an improvement over previously reported techniques. This method was used to evaluate the two compounds produced by BBI, the amino acid p-boronophenylalanine (BPA)and the sulfhydryl boroane N<sub>2</sub>B<sub>12</sub>H<sub>11</sub>SH (BSH), for clinically useful accumulation in a panel of human tumor cell lines. BPA showed selective accumulation in: squamous cell carcinoma of the lung; small cell carcinoma ... continued below

Creation Information

Coderre, J A & Spielvogel, B October 1, 1997.

Context

This report is part of the collection entitled: Office of Scientific & Technical Information Technical Reports and was provided by UNT Libraries Government Documents Department to Digital Library, a digital repository hosted by the UNT Libraries. It has been viewed 13 times . More information about this report can be viewed below.

Who

People and organizations associated with either the creation of this report or its content.

Sponsor

Publisher

Provided By

UNT Libraries Government Documents Department

Serving as both a federal and a state depository library, the UNT Libraries Government Documents Department maintains millions of items in a variety of formats. The department is a member of the FDLP Content Partnerships Program and an Affiliated Archive of the National Archives.

Contact Us

What

Descriptive information to help identify this report. Follow the links below to find similar items on the Digital Library.

Description

Boron neutron capture therapy (BNCT) is a binary treatment modality that can selectively irradiate tumor tissue. The key to effective BNCT is the preferential accumulation of <sup>10</sup>B in the tumor relative to the surrounding normal tissues. A screening procedure was developed under this CRADA that is an improvement over previously reported techniques. This method was used to evaluate the two compounds produced by BBI, the amino acid p-boronophenylalanine (BPA)and the sulfhydryl boroane N<sub>2</sub>B<sub>12</sub>H<sub>11</sub>SH (BSH), for clinically useful accumulation in a panel of human tumor cell lines. BPA showed selective accumulation in: squamous cell carcinoma of the lung; small cell carcinoma of the lung; osteosarcoma; prostate carcinoma; and ovarian carcinoma. Of these it was decided to pursue application of BPA-based BNCT to lung tumors. BPA distribution in nude mice bearing subcutaneous human lung tumor xenografts showed very favorable results. At 3 hours post-injection, the tumor/blood boron concentration ratio was 5:1, the tumorflung ratio was 6:1. The treatment planning sofiware, already in use for the glioblastoma BNCT clinical trial underway at BNL, was used for simulation of a human lung tumor treatment using BNCT. Input data for this simulation included the nude mouse biodistribution data, human lung tumor CT geometry, and the same assumptions about relative biological effectiveness of the BNCT dose components currently in use for the human brain tumor trial. The results of this lung tumor simulation indicate significant sparing of normal lung compared to tumor. We conclude that the BBI product BPA has potential applications in BNCT of other tumor sites. BPA-based BNCT for human small cell carcinoma of the lung looks promising. Further studies into the radiation biology of the normal lung will be required prior to clinical BNCT for lung tumors.

Language

Item Type

Identifier

Unique identifying numbers for this report in the Digital Library or other systems.

  • Report No.: DOE/CH/00016--T44
  • Report No.: BNL-83305-1997
  • Grant Number: AC02-76CH00016
  • DOI: 10.2172/770463 | External Link
  • Office of Scientific & Technical Information Report Number: 770463
  • Archival Resource Key: ark:/67531/metadc723102

Collections

This report is part of the following collection of related materials.

Office of Scientific & Technical Information Technical Reports

Reports, articles and other documents harvested from the Office of Scientific and Technical Information.

Office of Scientific and Technical Information (OSTI) is the Department of Energy (DOE) office that collects, preserves, and disseminates DOE-sponsored research and development (R&D) results that are the outcomes of R&D projects or other funded activities at DOE labs and facilities nationwide and grantees at universities and other institutions.

What responsibilities do I have when using this report?

When

Dates and time periods associated with this report.

Creation Date

  • October 1, 1997

Added to The UNT Digital Library

  • Sept. 29, 2015, 5:31 a.m.

Description Last Updated

  • Nov. 10, 2015, 1:55 p.m.

Usage Statistics

When was this report last used?

Yesterday: 0
Past 30 days: 1
Total Uses: 13

Interact With This Report

Here are some suggestions for what to do next.

Start Reading

PDF Version Also Available for Download.

International Image Interoperability Framework

IIF Logo

We support the IIIF Presentation API

Coderre, J A & Spielvogel, B. Medical Applications of Gadolinium and/or Boron-Labeled Pharmaceuticals, report, October 1, 1997; Upton, New York. (digital.library.unt.edu/ark:/67531/metadc723102/: accessed July 20, 2018), University of North Texas Libraries, Digital Library, digital.library.unt.edu; crediting UNT Libraries Government Documents Department.